Compound developed by CDRD and BCCA licensed

Guest Contributor
April 18, 2011

A new oncology compound developed by the Centre for Drug Research and Development and the BC Cancer Agency has been licensed to Baltimore, MD-based Champions Oncology Inc. Irinophore is a lipid-based nanoparticle developed by using a proprietary method developed by BCCA that has demonstrated the ability to ameliorate a critical side effect of Camptosan, the standard-of-care treatment for colorectal cancer. Irinophore is the first compound to be licensed as a result of collaboration between CDRD and BCCA. The drug is completing preclinical development and is slated to enter a Phase I clinical study in Q4/11 for the treatment of patients with advanced solid tumors….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.